Founding investors WuXi AppTec and Juno Therapeutics returned for a series A round that will support development of JW's cell-based therapy pipeline.
Pharmaceutical companies WuXi AppTec and Juno Therapeutics have contributed to a $90m series A round for China-based cell therapy technology startup JW Therapeutics that closed on Wednesday.
Singaporean state-owned investment firm Temasek also participated in the round, along with Sequoia Capital China, YuanMing Capital, Oriza Seed Capital, Yipu Capital and Avict Global Holdings.
WuXi, which is also known as WuXi PharmaTech, and Juno formed JW in 2016 to develop cell-based therapies by combining US-based immunotherapy developer Juno’s technology with China-headquartered…
